| Literature DB >> 21742519 |
Kunwar Awaneesh Singh1, Manasa K Nayak, Medicherla V Jagannadham, Debabrata Dash.
Abstract
Several anticoagulants, anti-platelet and thrombolytic medications are used for the treatment of thrombotic disorders. Anti-coagulants and anti-platelet agents prevent the formation of blood clots but do not dissolve existing clots, whereas thrombolytic agents are able to dissolve a clot but emboli can form even after successful treatment. Thus, none of them provide a permanent and complete solution. In this regard a single molecule that could both dissolve the clot and prevent the formation of new clots would be useful in the treatment of thrombotic diseases. Crinumin, a stable and active (in many adverse conditions) serine protease, shows plasmin-like fibrinolytic activity and inhibits platelet aggregation and P-selectin exposure, as established by photography, phase contrast microscopy, whole blood optical Lumi-aggregometry and flow cytometry. Crinumin could be an efficient and inexpensive therapeutic agent for the treatment and prevention of thromboembolic diseases.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21742519 DOI: 10.1016/j.bcmd.2011.06.003
Source DB: PubMed Journal: Blood Cells Mol Dis ISSN: 1079-9796 Impact factor: 3.039